Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study.
Julie ValentinThomas FertéValérie Dorizy-VuongLéa DoussetSorilla PreyCaroline DutriauxAnne Pham-LedardMarie Beylot-BarryEmilie GérardPublished in: Journal of oncology (2021)
This cohort shows a global recurrence rate of 18.5% and confirms a long-lasting response after anti-PD-1 cessation regardless of the cause of discontinuation.
Keyphrases